LYG-409
LYG-409 is an orally active degrader of GSPT1. LYG-409 shows excellent anti-acute myeloid leukemia and prostate cancer in vivo with TGI of 94.34% and 104.49%, respectively. LYG-409 inhibits KG-1 cells mediated by the degradation of GSPT1 with an IC50 of 9.50 nM, with a DC50 of 7.87 nM in vitro[1].
Product Specifications
CAS Number
3053857-55-6
UNSPSC
12352005
Target
Molecular Glues
Related Pathways
PROTAC
Applications
Cancer-programmed cell death
Field of Research
Cancer
Purity
98.11
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C1N(CC2=C1C=CC(CNC(C3=CC4=C(OC3)C=CC(OC(F)(F)F)=C4)=O)=C2)C5CCC(NC5=O)=O
Molecular Formula
C25H20F3N3O6
Molecular Weight
515.44
References & Citations
[1]Zhang Y, et al. Design and Discovery of Preclinical Candidate LYG-409 as a Highly Potent and Selective GSPT1 Molecular Glue Degraders. J Med Chem. 2025 Feb 13;68 (3) :2608-2638.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
